Board Member
Lb Pharmaceuticals Inc (LBRX)Board Member
Terns Pharmaceuticals, Inc.
Equibles does not estimate personal net worth.
Get an email with a short summary when Lb Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get LBRX alertsHeather Turner is recorded as CEO and Board Member at Lb Pharmaceuticals Inc (LBRX) and Board Member at Terns Pharmaceuticals, Inc. since January 1, 2024. The newest filing on record that lists Heather Turner as CEO and Board Member at Lb Pharmaceuticals Inc (LBRX) is dated April 23, 2026. The newest filing on record that lists Heather Turner as Board Member at Terns Pharmaceuticals, Inc. is dated April 29, 2025. Heather Turner was last confirmed as General Counsel at Lyell Immunopharma, Inc. (LYEL) in a filing dated April 28, 2022. Terns Pharmaceuticals, Inc. reported in an 8-K filed November 18, 2024 that Heather Turner was appointed member of the Board, effective November 18, 2024. The proxy statement of Lb Pharmaceuticals Inc reports total compensation of $11,884,985 for Heather Turner in fiscal 2025, including a base salary of $568,750. Disclosed compensation is on record for 2 fiscal years. Heather Turner has spoken on 1 investor event across 1 company, most recently for Lb Pharmaceuticals Inc on June 16, 2026. Lb Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Terns Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lb Pharmaceuticals Inc includes Joseph M. Miller (CFO), Gad Soffer (COO) and Robert A. Lenz (Board Member).
“On November 15, 2024, the Board appointed and elected Heather Turner as a member of the Board, effective as of November 18, 2024.”
“The company was founded in 2015 by three different founders, one of which was a pharmacist in the prison system and had familiarity with AmiSolPride. And the group of them set out to see if there was an opportunity to bring it to the United States.”
Terns Pharmaceuticals, Inc.
Board Member
Proxy statement
2024-01-01–present
Last confirmed April 29, 2025
Start not stated–present
Last confirmed April 23, 2026
Start not stated–present
Last confirmed April 23, 2026
Start not stated–2022-04-28
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Board Member
Terns Pharmaceuticals, Inc.
Biotechnology · Healthcare
Board Member
2024-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Lb Pharmaceuticals Inc (LBRX) | Chief Executive Officer | $568,750 | $11,884,985 |
| 2024 | Lb Pharmaceuticals Inc (LBRX) | Chief Executive Officer | $68,750 | $4,792,690 |
